Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

This review critically evaluates the evidence for SARMs' tissue selectivity and suggests their clinical benefits over traditional androgens are not yet well-supported by robust evidence, underscoring the need for further head-to-head trials.

This project by the International Society of Hair Restoration Surgery aims to define best practices in hair restoration surgery but does not report new clinical findings.

In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.

This study found that abrocitinib showed promising efficacy and safety in adolescents with moderate-to-severe alopecia areata, with significant hair regrowth observed over 10 months of treatment.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

This study found that intramuscular triamcinolone acetonide may be an effective and safe treatment option for managing refractory alopecia areata, showing a 63% response rate in patients and hair regrowth negatively correlated with initial scalp involvement.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

In this case report, the authors describe using Polarity Analysis for selecting homeopathic remedies to better match patient symptoms in treating alopecia areata, offering a potential alternative to corticosteroids, which are associated with significant side effects.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

5-ARI therapy may help prevent prostate cancer progression.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

A comprehensive approach is needed to accurately assess alopecia areata severity and guide treatment decisions.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

This review provides insights and guidelines for clinicians and patients on assessing the risks and benefits of ritlecitinib for adolescents with alopecia areata, emphasizing shared decision-making and management strategies.

This study found that at Week 52, baricitinib resulted in significant hair regrowth for many patients with severe alopecia areata, with 41.6% on the higher dose achieving substantial improvement in scalp hair loss, though some may need longer treatment for optimal benefit.

This study found that generic quality of life questionnaires, like the SF-36 and DLQI, are not sensitive enough to detect differences in health-related quality of life between patients with varying severity of alopecia areata.

Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.

This study suggests that while adding baricitinib to formularies may increase costs for government hospitals, it could expand treatment options and potentially improve outcomes for patients with AA. Further analyses are recommended to assess its cost-effectiveness in terms of outcomes improvement.

This review discusses the relevance of human androgen receptor action in sports doping and examines the potential of cell-based biological assays for detecting androgenic anabolic steroid use, without presenting new research findings.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.